Search PubMed⌕ Search

Biomedical subjects

E Jassem

Publications and source records attributed to E Jassem.

42 records · Page 3Linked to original sources
PubMed1990

Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma.

10 patients with locally advanced bronchioloalveolar carcinoma were treated with interferon-alpha as an inhaled aerosol. Initial doses ranged between 1 and 10 MU daily or thrice weekly and were then increased to 20 MU daily. Treatment was continued until disease progression or excessive toxicity occurred, 9 patients were evaluable for toxicity. In 1 case treatment had to be stopped after 2 weeks due to fever, fatigue and progressive dyspnoea. 2 patients developed fever, 1 had malaise, fatigue and loss of appetite and 2 had dose-dependent transient dyspnoea. According to standard criteria no tumour responses could be detected. In 6 out of 8 evaluated for response to interferon, radiological stabilisation of disease for 7-43 weeks (median 15) was observed. These results point to the feasibility of aerosol inhalation of interferon-alpha, but also to its limited antitumour activity in locally advanced bronchioloalveolar carcinoma.

Adenocarcinoma, Bronchiolo-Alveolar↗
PubMed1990

Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma.

Serum levels of NSE were monitored in 20 SCLC patients who completely responded to combination chemotherapy. An elevation of NSE was observed in five of nine patients with recurrent disease, but predated a relapse in only one. No elevation in NSE level was noted in nine patients who remained in complete remission. The addition of serial assays of LDH to NSE monitoring did not result in any gain in early warning of relapse. This study suggests that the value of serial NSE measurements for predicting a relapse of disease is limited.

Adult↗
PubMedDate not supplied

Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer.

S-100 protein expression is present in various malignant tissues, yet its prognostic relevance is debatable. The aim was to assess in non-small cell lung cancer (NSCLC) patients' prognostic value of S-100 protein considered alone or in relation with other variables. Tumour samples taken from 86 NSCLC patients during resection were assayed for S-100 protein expression with the use of polyclonal DAKO ZO311 antibody. S-100 expression was found in 32 cases (37%). Positive staining was not correlated with clinical characteristics including age, sex, pathology type of tumour, stage and cigarette smoking. There was a tendency for simultaneous expression of S-100 and P53 protein (p=0.06). A median survival rate for the entire group was 2.3 years (95% CI, 0.9-3.6 years). The median and 5-year survival of patients with positive staining for S-100 protein was 1.5 years and 25%, respectively, compared with 3.0 years and 35%, respectively, in the S-100 negative group (p=0.17). In the final model of a multivariate analysis, S-100 protein expression in tumour cells was associated with significantly decreased survival (p=0.005). S-100 protein expression in tumour cells seems to be an independent predictor of poor prognosis in NSCLC patients.

Adult↗